financetom
Business
financetom
/
Business
/
Evolv Technologies Says Internal Probe Reveals Revenue Recognition Inaccuracies
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Evolv Technologies Says Internal Probe Reveals Revenue Recognition Inaccuracies
Oct 26, 2024 4:33 AM

08:59 AM EDT, 10/25/2024 (MT Newswires) -- Evolv Technologies Holdings ( EVLV ) said Friday that it is delaying its third-quarter earnings report and Form 10-Q filing because certain past financial statements should not be relied upon due to inaccuracies in revenue recognition.

The company said the board's ad hoc committee is conducting an internal investigation into its sales practices. Preliminary findings suggest that some sales involved extra-contractual terms, leading to premature or incorrect revenue recognition between Q2 2022 and Q2 2024, Evolv ( EVLV ) said.

The maker of AI-based weapons detection systems said the committee also found that "certain Company personnel engaged in misconduct in connection with those transactions."

The misstatements are estimated to have resulted in revenue discrepancies of $4 million to $6 million, Evolv ( EVLV ) added.

The company said is working on amending the affected financial statements and has notified the US Securities and Exchange Commission, which is already investigating an "unrelated" matter.

Evolv ( EVLV ) said in February that the SEC had opened a confidential non-public, fact-finding inquiry into the company.

Shares of Evolv ( EVLV ) were down more than 34% in recent Friday premarket activity.

Price: 2.7000, Change: -1.40, Percent Change: -34.15

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Novo Nordisk Says Wegovy Results in Higher Weight Loss With Higher Dosage
Novo Nordisk Says Wegovy Results in Higher Weight Loss With Higher Dosage
Jun 23, 2025
06:20 AM EDT, 06/23/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Sunday that participants with obesity in a phase 3 study met its primary endpoint of greater weight loss with a higher 7.2mg dose of Wegovy. Patients showed mean weight loss of 20.7%, with a third of participants losing 25% or more, compared with 17.4% for those taking...
South Africa's Takealot grows revenue to fend off Amazon rivalry
South Africa's Takealot grows revenue to fend off Amazon rivalry
Jun 23, 2025
* Takealot Group revenue grows 15% to $872 mln * Invests in logistics, offerings and subscription service * Focus on loyalty program, AI, product range to keep market share (Recasts throughout with South African e-commerce business) By Nqobile Dludla JOHANNESBURG, June 23 (Reuters) - South Africa's biggest online retail group Takealot grew its full-year revenue by 15%, with growth supported...
Novo Nordisk Says Study Shows Statistically Significant Weight Loss in Adults Treated With CagriSema
Novo Nordisk Says Study Shows Statistically Significant Weight Loss in Adults Treated With CagriSema
Jun 23, 2025
06:21 AM EDT, 06/23/2025 (MT Newswires) -- Novo Nordisk A/S ( NVO ) announced on Sunday that its Phase 3 REDEFINE 1 trial, evaluating CagriSema for weight loss in overweight or obese adults without diabetes, met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss compared to placebo. The study showed that treatment with CagriSema resulted in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved